Lv41
580 积分 2023-10-12 加入
A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities
1小时前
已完结
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
6天前
已完结
Therapeutic potential of cis-targeting bispecific antibodies
13天前
已完结
Interleukin 15 as a promising candidate for tumor immunotherapy
13天前
已完结
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer
20天前
已完结
Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
29天前
已完结
Analyzing the Tumor Microenvironment by Flow Cytometry
1个月前
已完结
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
1个月前
已完结
The IL-2/IL-15 receptor systems: targets for immunotherapy
1个月前
已完结
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
2个月前
已完结
皖公网安备34019202002308
